FIGS, Inc. has emerged as a specialized player in the medical apparel sector. The company generated strong financial performance through late 2025, but questions about valuation and growth sustainability have surfaced in early 2026.
The company delivered robust Q3 2025 results, with sales exceeding market expectations and adjusted EBITDA above consensus. Regional sales growth was particularly strong.
Gross margin reached 66.61%, significantly above industry averages. Operational expense normalization also boosted profitability.
Following strong results, management raised Q4 2025 guidance. Analysts have maintained a cautious stance, with Barclays setting a $9.00 price target.
Shares trade at $12.54, delivering a 185% return over the past year. The company focuses on premium products for healthcare professionals. International expansion presents a key growth opportunity.
